Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Abstract Background Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-posi...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana, Ammarin Thakkinstian
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2019-11-01
Cyfres:	BMC Health Services Research
Pynciau:	Adjuvant trastuzumab Cost-utility analysis HER2-positive Breast cancer Cost-effectiveness Philippines
Mynediad Ar-lein:	http://link.springer.com/article/10.1186/s12913-019-4715-8
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!